GSK: ViiV's HIV two-drug regimen shows positive results
(CercleFinance.com) - Phase III data showed ViiV Healthcare's two-drug regimen of dolutegravir and lamivudine has similar efficacy to a three-drug regimen in treatment-naïve HIV patients, with no emergence of resistance.
The company, formed in 2009 by GlaxoSmithKline and Pfizer, today presented 48-week results from two phase-III studies at the AIDS conference in Amsterdam, assessing the safety and efficacy of a two-drug regimen of dolutegravir and lamivudine compared to a three-drug regimen.
The studies met their primary endpoint for non-inferiority based on standard measure of HIV control, it said.
While the standard of care for HIV has revolved around three-drug regimens for the last 15-20 years, the focus is now shifting to two-drug regimens with the same tolerability and drug interaction profile.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The company, formed in 2009 by GlaxoSmithKline and Pfizer, today presented 48-week results from two phase-III studies at the AIDS conference in Amsterdam, assessing the safety and efficacy of a two-drug regimen of dolutegravir and lamivudine compared to a three-drug regimen.
The studies met their primary endpoint for non-inferiority based on standard measure of HIV control, it said.
While the standard of care for HIV has revolved around three-drug regimens for the last 15-20 years, the focus is now shifting to two-drug regimens with the same tolerability and drug interaction profile.
Copyright (c) 2018 CercleFinance.com. All rights reserved.